Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TulmiSTAR-02
NCT07190300Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jan 2026
- Primary completion
- Aug 2032
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of tulmimetostat in prostate cancer (PCa), sponsored by Novartis. Started Jan 2026; status: recruiting.
02
Drugs
tulmimetostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07190300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190300.